Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

Abstract

In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19 + acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 147

1. 1.

   Noone, A. M. et al. SEER Cancer Statistics Review, 1975–2015. National Cancer Institutehttps://seer.cancer.gov/csr/1975_2015/ (2018).

   Not in our library

2. 2.

   Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 1948;238:787-793.

   Not in our library10.1056/nejm194806032382301

3. 3.

   O’Leary M, Krailo M, Anderson JR, Reaman GH, Children’s Oncology Group. Progress in childhood cancer: 50 years of research collaboration, a report from the Children’s Oncology Group. Semin. Oncol. 2008;35:484-493.

   Not in our library10.1053/j.seminoncol.2008.07.008

4. 4.

   Blau, C. A. E. Donnall Thomas, M.D. (1920–2012). Stem Cells Transl Med. (2013).

   Not in our library

5. 5.

   Ko RH, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J. Clin. Oncol. 2010;28:648-654.

   Not in our library10.1200/jco.2009.22.2950

6. 6.

   Sun, W. et al. Outcome of children with multiply relapsed B cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia and lymphoma study. Leukemia10.1038/s41375-018-0094-0 (2018).

   Not in our library10.1038/s41375-018-0094-0

7. 7.

   Thomas ED, et al. Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood. 1979;54:468-476.

   Not in our library

8. 8.

   Novartis Pharmaceuticals Corporation. Package insert - KymriahTM (tisagenlecleucel). Novartis Pharmaceuticals Corporationhttps://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM573941.pdf (2018).

   Not in our library

9. 9.

   Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014;371:1507-1517.

   Not in our library10.1056/nejmoa1407222

10. 10.

    Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J. Natl Cancer Inst. 2016;108:djv439.

    Not in our library10.1093/jnci/djv439

11. 11.

    Kebriaei P, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J. Clin. Invest. 2016;126:3363-3376.

    Not in our library10.1172/jci86721

12. 12.
    CAR models: next-generation CAR modifications for enhanced T-cell function · 2016

    Not checked
13. 13.

    Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist. 2016;21:608-617.

    Not in our library10.1634/theoncologist.2015-0421

14. 14.

    Kochenderfer JN, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099-4102.

    Not in our library10.1182/blood-2010-04-281931

15. 15.

    Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011;365:725-733.

    Not in our library10.1056/nejmoa1103849

16. 16.

    Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013;368:1509-1518.

    Not in our library10.1056/nejmoa1215134

17. 17.

    Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl Med. 2013;5:177ra138.

    Not in our library10.1126/scitranslmed.3005930

18. 18.

    Cruz CR, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122:2965-2973.

    Not in our library10.1182/blood-2013-06-506741

19. 19.

    Kochenderfer JN, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129-4139.

    Not in our library10.1182/blood-2013-08-519413

20. 20.

    Davila ML, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl Med. 2014;6:224ra225.

    Not in our library10.1126/scitranslmed.3008226

21. 21.

    Kochenderfer JN, et al. Chemotherapy-refractory diffuse large B cell lymphoma and indolent B cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 2015;33:540-549.

    Not in our library10.1200/jco.2014.56.2025

22. 22.

    Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517-528.

    Not in our library10.1016/s0140-6736(14)61403-3

23. 23.

    Garfall AL, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 2015;373:1040-1047.

    Not in our library10.1056/nejmoa1504542

24. 24.

    Brudno JN, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 2016;34:1112-1121.

    Not in our library10.1200/jco.2015.64.5929

25. 25.

    Turtle CJ, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J. Clin. Oncol. 2017;35:3010-3020.

    Not in our library10.1200/jco.2017.72.8519

26. 26.

    Locke FL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 2017;25:285-295.

    Not in our library10.1016/j.ymthe.2016.10.020

27. 27.

    Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 2017;377:2531-2544.

    Not in our library10.1056/nejmoa1707447

28. 28.

    Kochenderfer JN, et al. B cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709-2720.

    Not in our library10.1182/blood-2011-10-384388

29. 29.

    Lee DW, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-195.

    Not in our library10.1182/blood-2014-05-552729

30. 30.

    Teachey DT, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154-5157.

    Not in our library10.1182/blood-2013-02-485623

31. 31.
    The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer · 2015

    No notice
32. 32.

    Richman SA, et al. High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer. Immunol. Res. 2018;6:36-46.

    Not in our library10.1158/2326-6066.cir-17-0211

33. 33.

    Fitzgerald JC, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit. Care Med. 2017;45:e124-e131.

    Not in our library10.1097/ccm.0000000000002053

34. 34.

    Norelli M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 2018;24:739-748.

    Not in our library10.1038/s41591-018-0036-4

35. 35.

    Giavridis T, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 2018;24:731-738.

    Not in our library10.1038/s41591-018-0041-7

36. 36.

    FDA. FDA briefing document: Oncologic Drugs Advisory Committee meeting; BLA 125646; Tisagenlecleucel, Novartis Pharmaceuticals Corporation. FDAhttps://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566166.pdf (2017).

    Not in our library

37. 37.

    Neelapu SS, et al. Chimeric antigen receptor T cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 2018;15:47-62.

    Not in our library10.1038/nrclinonc.2017.148

38. 38.

    Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 2018;378:439-448.

    Not in our library10.1056/nejmoa1709866

39. 39.

    Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am. J. Publ. Health. 1984;74:979-983.

    Not in our library10.2105/ajph.74.9.979

40. 40.

    Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Developing clinical guidelines. West J. Med. 1999;170:348-351.

    Not in our library

41. 41.

    Shields AF, et al. Immune modulation therapy and imaging: workshop report. J. Nucl. Med. 2018;59:410-417.

    Not in our library10.2967/jnumed.117.195610

42. 42.

    Massad N, Lee SC, Lasala PA, Welch MR. A case of pembrolizumab-induced central nervous system toxicity in a patient with metastatic melanoma. Am. Acad. Neurol. 2016;86:P4.238.

    Not in our library

43. 43.

    Hochmair MJ, Schwab S, Burghuber OC, Krenbek D, Prosch H. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. Lung Cancer. 2017;113:4-6.

    Not in our library10.1016/j.lungcan.2017.08.020

44. 44.

    [No authors listed.] Informed consent, parental permission, and assent in pediatric practice. Committee on Bioethics, American Academy of Pediatrics. Pediatrics95, 314–317 (1995).

    Not in our library

45. 45.

    McGuirk J, et al. Building blocks for institutional preparation of CTL019 delivery. Cytotherapy. 2017;19:1015-1024.

    Not in our library10.1016/j.jcyt.2017.06.001

46. 46.

    Gardner RA, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322-3331.

    Not in our library10.1182/blood-2017-02-769208

47. 47.

    Crookston, K. P. & Simon, T. L. in Apheresis: Principles and Practice 2nd edn (eds McLeod, B. C., Price, T. H. & Weinstein, R.) 71–90 (AABB Press, Bethesda, 2003).

    Not in our library

48. 48.

    Goldstein SL. Therapeutic apheresis in children: special considerations. Semin. Dial. 2012;25:165-170.

    Not in our library10.1111/j.1525-139x.2011.01028.x

49. 49.

    US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT02028455 (2018).

    Not in our library

50. 50.

    Michon B, et al. Complications of apheresis in children. Transfusion. 2007;47:1837-1842.

    Not in our library10.1111/j.1537-2995.2007.01405.x

51. 51.

    Gorlin JB, et al. Pediatric large volume peripheral blood progenitor cell collections from patients under 25 kg: a primer. J. Clin. Apheresis. 1996;11:195-203.

    Not in our library10.1002/(sici)1098-1101(1996)11:4<195::aid-jca4>3.0.co;2-6

52. 52.

    Carausu L, Clapisson G, Philip I, Sebban H, Marec-Berard P. Use of totally implantable catheter for peripheral blood stem cell apheresis. Bone Marrow Transpl. 2007;39:S131-S131.

    Not in our library10.1038/sj.bmt.1705756

53. 53.

    Koristek Z, Sterba J, Havranova D, Mayer J. Technique for PBSC harvesting in children of weight under 10 kg. Bone Marrow Transpl. 2002;29:57-61.

    Not in our library10.1038/sj.bmt.1703334

54. 54.

    Ohara Y, et al. Comprehensive technical and patient-care optimization in the management of pediatric apheresis for peripheral blood stem cell harvesting. Transfus Apher Sci. 2016;55:338-343.

    Not in our library10.1016/j.transci.2016.09.014

55. 55.

    Foundation for the Accreditation of Cellular Therapy. FACT Standards for Immune Effector Cells. 1st edn (FACT, 2017).

    Not in our library

56. 56.

    Wells J, et al. Pre-clinical activity of allogeneic anti-CD22 CAR-T cells for the treatment of B-cell acute lymphoblastic leukemia. Blood. 2017;130:808.

    Not in our library

57. 57.

    US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT03056339 (2018).

    Not in our library

58. 58.

    US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT02808442 (2018).

    Not in our library

59. 59.

    Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol. Ther. 2017;25:1769-1781.

    Not in our library10.1016/j.ymthe.2017.06.012

60. 60.

    Liu E, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2017;32:520-531.

    Not in our library10.1038/leu.2017.226

61. 61.

    Philip, B. RQR8: A universal safety switch for cellular therapies. Thesis, Univ. College London (2015).

    Not in our library

62. 62.

    Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20:119-122.

    Not in our library10.1097/ppo.0000000000000035

63. 63.

    Tomblyn M, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transplant. 2009;15:1143-1238.

    Not in our library10.1016/j.bbmt.2009.06.019

64. 64.

    Turtle CJ, et al. CD19 CAR-T cells of defined CD4(+): CD8(+) composition in adult B cell ALL patients. J. Clin. Invest. 2016;126:2123-2138.

    Not in our library10.1172/jci85309

65. 65.

    Dudley ME, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005;23:2346-2357.

    Not in our library10.1200/jco.2005.00.240

66. 66.

    Dummer W, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 2002;110:185-192.

    Not in our library10.1172/jci15175

67. 67.

    Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26:111-117.

    Not in our library10.1016/j.it.2004.12.003

68. 68.

    Mackall CL, Hakim FT, Gress RE. Restoration of T cell homeostasis after T cell depletion. Semin. Immunol. 1997;9:339-346.

    Not in our library10.1006/smim.1997.0091

69. 69.

    Tanchot C, Lemonnier FA, Perarnau B, Freitas AA, Rocha B. Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science. 1997;276:2057-2062.

    Not in our library10.1126/science.276.5321.2057

70. 70.

    Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity. 1999;11:183-190.

    Not in our library10.1016/s1074-7613(00)80093-x

71. 71.

    Tan JT, et al. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. 2002;195:1523-1532.

    Not in our library10.1084/jem.20020066

72. 72.

    Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 2000;1:426-432.

    Not in our library10.1038/80868

73. 73.

    Tan JT, et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl Acad. Sci. USA. 2001;98:8732-8737.

    Not in our library10.1073/pnas.161126098

74. 74.

    Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999;163:5211-5218.

    Not in our library

75. 75.

    Colombo MP, Piconese S. Regulatory-T cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer. 2007;7:880-887.

    Not in our library10.1038/nrc2250

76. 76.

    Wrzesinski C, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 2010;33:1-7.

    Not in our library10.1097/cji.0b013e3181b88ffc

77. 77.

    Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006;6:383-393.

    Not in our library10.1038/nri1842

78. 78.

    Cameron J, et al. Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T Cells and clinical outcome in adults with B cell acute lymphoblastic leukemia. Blood. 2015;126:3773.

    Not in our library

79. 79.

    Heczey A, et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol. Ther. 2017;25:2214-2224.

    Not in our library10.1016/j.ymthe.2017.05.012

80. 80.

    Shank BR, et al. Chimeric antigen receptor T cells in hematologic malignancies. Pharmacotherapy. 2017;37:334-345.

    Not in our library10.1002/phar.1900

81. 81.

    Brentjens RJ, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B cell leukemias. Blood. 2011;118:4817-4828.

    Not in our library10.1182/blood-2011-04-348540

82. 82.

    Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321-3330.

    Not in our library10.1182/blood-2016-04-703751

83. 83.

    US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT02203825 (2018).

    Not in our library

84. 84.

    Leukemia & Lymphoma Society. Chimeric antigen receptor (CAR) T-cell therapy. Leukemia & Lymphoma Societyhttps://www.lls.org/sites/default/files/National/USA/Pdf/Publications/FSHP1_CART_Factsheet_June2018_FINAL.pdf (2017).

    Not in our library

85. 85.

    Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 2010;18:666-668.

    Not in our library10.1038/mt.2010.31

86. 86.

    Truong TH, et al. Adverse reactions during stem cell infusion in children treated with autologous and allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:680-686.

    Not in our library10.1038/bmt.2015.331

87. 87.

    Davis JM, Rowley SD, Braine HG, Piantadosi S, Santos GW. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood. 1990;75:781-786.

    Not in our library

88. 88.

    Stroncek DF, et al. Adverse reactions in patients transfused with cryopreserved marrow. Transfusion. 1991;31:521-526.

    Not in our library10.1046/j.1537-2995.1991.31691306250.x

89. 89.

    Zambelli A, et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res. 1998;18:4705-4708.

    Not in our library

90. 90.

    Zenhausern R, Tobler A, Leoncini L, Hess OM, Ferrari P. Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. Ann. Hematol. 2000;79:523-526.

    Not in our library10.1007/s002770000186

91. 91.

    Hoyt R, Szer J, Grigg A. Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells. Bone Marrow Transplant. 2000;25:1285-1287.

    Not in our library10.1038/sj.bmt.1702443

92. 92.

    Otrock ZK, et al. Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells. Haematologica. 2008;93:e36-e37.

    Not in our library10.3324/haematol.12249

93. 93.

    Miniero R, Vai S, Giacchino M, Giubellino C, Madon E. Severe respiratory depression after autologous bone marrow infusion. Haematologica. 1992;77:98-99.

    Not in our library

94. 94.

    Shu Z, Heimfeld S, Gao D. Hematopoietic stem cell transplantation with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal prior to infusion. Bone Marrow Transpl. 2014;49:469-476.

    Not in our library10.1038/bmt.2013.152

95. 95.

    Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin. J. Oncol. Nurs. 2007;11:37-42.

    Not in our library10.1188/07.cjon.s1.37-42

96. 96.

    Namuduri M, Brentjens RJ. Medical management of side effects related to CAR T cell therapy in hematologic malignancies. Expert Rev. Hematol. 2016;9:511-513.

    Not in our library10.1080/17474086.2016.1183479

97. 97.

    Buechner J, et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): update to the interim analysis. Clin. Lymphoma Myeloma Leuk. 2017;17:S263-S264.

    Not in our library

98. 98.

    Power N, Franck L. Parent participation in the care of hospitalized children: a systematic review. J. Adv. Nurs. 2008;62:622-641.

    Not in our library10.1111/j.1365-2648.2008.04643.x

99. 99.

    U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. U.S. Department of Health and Human Services.https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (2017).

    Not in our library

100. 100.

     Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr. Crit. Care Med. 2015;16:428-439.

     Not in our library10.1097/pcc.0000000000000350

101. 101.

     Rowan CM, et al. Pediatric acute respiratory distress syndrome in pediatric allogeneic hematopoietic stem cell transplants: a multicenter study. Pediatr. Crit. Care Med. 2017;18:304-309.

     Not in our library10.1097/pcc.0000000000001061

102. 102.

     Rowan CM, et al. High-frequency oscillatory ventilation use and severe pediatric ARDS in the pediatric hematopoietic cell transplant recipient. Respir. Care. 2017;63:404-411.

     Not in our library10.4187/respcare.05765

103. 103.

     Chong SL, et al. A retrospective review of vital signs and clinical outcomes of febrile infants younger than 3 months old presenting to the emergency department. PLOS One. 2018;13:e0190649.

     Not in our library10.1371/journal.pone.0190649

104. 104.

     Fleming S, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet. 2011;377:1011-1018.

     Not in our library10.1016/s0140-6736(10)62226-x

105. 105.

     Akcan-Arikan A, et al. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71:1028-1035.

     Not in our library10.1038/sj.ki.5002231

106. 106.

     Kidney Disease Improving Global Outcomes. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2012;2:1-138.

     Not in our library

107. 107.

     Neelapu SS, et al. Axicabtagene ciloleucel (AXI-CEL; KTE-C19) in patients with refractory aggressive non-hodgkin lymphomas (NHL): primary results of the pivotal trial ZUMA-1. Hematol.Oncol. 2017;35:28.

     Not in our library

108. 108.

     Thudium Mueller K, et al. CTL019 clinical pharmacology and biopharmaceutics in pediatric patients (pts) with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) [abstract ALL-146]. Clin. Lymphoma Myeloma Leuk. 2017;17:217-218.

     Not in our library

109. 109.

     FDA. FDA approves tisagenlecleucel for B cell ALL and tocilizumab for cytokine release syndrome. FDAhttps://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm574154.htm (2017).

     Not in our library

110. 110.

     Genentech. ACTEMRA® (tocilizumab) prescribing information. FDAhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf (2017).

     Not in our library

111. 111.

     Chen F, et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J. Immunol. Methods. 2016;434:1-8.

     Not in our library10.1016/j.jim.2016.03.005

112. 112.

     Minoia F, et al. Development and initial validation of the macrophage activation syndrome/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome. J. Pediatr. 2017;189:72-78.

     Not in our library10.1016/j.jpeds.2017.06.005

113. 113.

     Henter JI, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer. 2007;48:124-131.

     Not in our library10.1002/pbc.21039

114. 114.

     Frey NV, et al. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells. Blood. 2014;124:2296.

     Not in our library

115. 115.
     Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy · 2016

     No notice
116. 116.

     Traube C, et al. Cornell assessment of pediatric delirium: a valid, rapid, observational tool for screening delirium in the PICU. Crit. Care Med. 2014;42:656-663.

     Not in our library10.1097/ccm.0b013e3182a66b76

117. 117.

     Silver G, Kearney J, Traube C, Hertzig M. Delirium screening anchored in child development: the Cornell Assessment for Pediatric Delirium. Palliat. Support. Care. 2015;13:1005-1011.

     Not in our library10.1017/s1478951514000947

118. 118.

     Gust J, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404-1419.

     Not in our library10.1158/2159-8290.cd-17-0698

119. 119.

     Taraseviciute A, et al. Chimeric antigen receptor T cell-mediated neurotoxicity in non-human primates. Cancer Discov. 2018;8:750-763.

     Not in our library10.1158/2159-8290.cd-17-1368

120. 120.

     Turtle CJ, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl Med. 2016;8:355ra116.

     Not in our library10.1126/scitranslmed.aaf8621

121. 121.

     Teachey DT, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664-679.

     Not in our library10.1158/2159-8290.cd-16-0040

122. 122.

     Stephen J, et al. Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood. 2015;126:183-183.

     Not in our library

123. 123.

     Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy. 2001;21:1375-1388.

     Not in our library10.1592/phco.21.17.1375.34432

124. 124.

     Guenther S, et al. Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans. Seizure. 2014;23:666-669.

     Not in our library10.1016/j.seizure.2014.04.011

125. 125.

     Perez EE, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J. Allergy Clin. Immunol. 2017;139:S1-S46.

     Not in our library10.1016/j.jaci.2016.09.023

126. 126.

     Weissert R. Progressive multifocal leukoencephalopathy. J. Neuroimmunol. 2011;231:73-77.

     Not in our library10.1016/j.jneuroim.2010.09.021

127. 127.

     Durali D, de Goer de Herve MG, Gasnault J, Taoufik Y. B cells and progressive multifocal leukoencephalopathy: search for the missing link. Front. Immunol. 2015;6:241.

     Not in our library10.3389/fimmu.2015.00241

128. 128.

     Abdel-Azim H, Elshoury A, Mahadeo KM, Parkman R, Kapoor N. Humoral immune reconstitution kinetics after allogeneic hematopoietic stem cell transplantation in children: a maturation block of IgM memory B cells may lead to impaired antibody immune reconstitution. Biol. Blood Marrow Transplant. 2017;23:1437-1446.

     Not in our library10.1016/j.bbmt.2017.05.005

129. 129.

     Dalba C, Bellier B, Kasahara N, Klatzmann D. Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol. Ther. 2007;15:457-466.

     Not in our library10.1038/sj.mt.6300054

130. 130.

     Centre for Biologics Evaluation and Research. Gene therapy clinical trials–observing subjects for delayed adverse events. FDAhttps://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm078719.pdf (2006).

     Not in our library

131. 131.

     Centre for Biologics Evaluation and Research. Supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors. FDAhttps://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/cellularandgenetherapy/ucm078723.pdf (2006).

     Not in our library10.1089/10430340150218440

132. 132.

     Bennett TD, et al. Existing data analysis in pediatric critical care research. Front. Pediatr. 2014;2:79.

     Not in our library10.3389/fped.2014.00079

133. 133.

     Cope S, et al. Expert elicitation of long-term survival for pediatric acute lymphoblastic leukemia patients receiving CTL019 in Eliana phase II study. Blood. 2017;130:3377.

     Not in our library

134. 134.

     Jackson HJ, Brentjens RJ. Overcoming antigen escape with CAR T cell therapy. Cancer Discov. 2015;5:1238-1240.

     Not in our library10.1158/2159-8290.cd-15-1275

135. 135.

     Doorenbos A, et al. Palliative care in the pediatric ICU: challenges and opportunities for family-centered practice. J. Soc. Work End Life Palliat Care. 2012;8:297-315.

     Not in our library10.1080/15524256.2012.732461

136. 136.

     Yanni Hao LK. Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the United States. Blood. 2017;130:609.

     Not in our library

137. 137.

     LaMattina, J. Pharma’s paradox: cure a deadly childhood disease and then get attacked on price. Forbeshttps://www.forbes.com/sites/johnlamattina/2017/11/28/cure-a-deadly-childhood-disease-and-then-get-attacked-on-price/#7089d1696479 (2017).

     Not in our library

138. 138.

     Prasad V. Immunotherapy: tisagenlecleucel - the first approved CAR-T cell therapy: implications for payers and policy makers. Nat. Rev. Clin. Oncol. 2018;15:11-12.

     Not in our library10.1038/nrclinonc.2017.156

139. 139.

     Sanders GD, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093-1103.

     Not in our library10.1001/jama.2016.12195

140. 140.

     Gold M. Panel on cost-effectiveness in health and medicine. Med. Care. 1996;34:DS197-199.

     Not in our library

141. 141.

     American Nurses Association. Care coordination and nurses’ essential role. Am. Nurses Associ.https://www.nursingworld.org/~4afbf2/globalassets/practiceandpolicy/health-policy/cnpe-care-coord-position-statement-final--draft-6-12-2012.pdf (2012).

     Not in our library

142. 142.

     Antonelli RC, Stille CJ, Antonelli DM. Care coordination for children and youth with special health care needs: a descriptive, multisite study of activities, personnel costs, and outcomes. Pediatrics. 2008;122:e209-e216.

     Not in our library10.1542/peds.2007-2254

143. 143.

     FDA. Approved Risk Evaluation and Mitigation Strategies (REMS) for KymriahTM(tisagenlecleucel). FDAhttps://www.Accessdata.fda.gov/Scripts/Cder/Rems/Index.cfm?Event=IndvRemsDetails.Page&REMS=368 (2017).

     Not in our library

144. 144.

     Bayntun C, Rockenschaub G, Murray V. Developing a health system approach to disaster management: A qualitative analysis of the core literature to complement the WHO Toolkit for assessing health-system capacity for crisis management. PLOS Curr. 2012;4:e5028b6037259a.

     Not in our library10.1371/5028b6037259a

145. 145.

     Kevin H, Morchel H, Raheem M, Stevens L. Electronic health records access during a disaster. Online J. Publ. Health Inform. 2014;5:232.

     Not in our library10.5210/ojphi.v5i3.4826

146. 146.

     Wingard JR, et al. Preparing for the unthinkable: emergency preparedness for the hematopoietic cell transplant program. Biol. Blood Marrow Transplant. 2006;12:1229-1238.

     Not in our library10.1016/j.bbmt.2006.08.001

147. 147.

     Frisen L. Swelling of the optic nerve head: a staging scheme. J. Neurol. Neurosurg. Psychiatry. 1982;45:13-18.

     Not in our library10.1136/jnnp.45.1.13

Cited by papers we hold 4

• Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies · 2021
  No notice
• The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma · 2020
  No notice
• Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies · 2020
  No notice
• CAR T Cell Toxicity: Current Management and Future Directions · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.